

Synthesis and antimalarial activity screening of artemisinin-acridine hybrids

Juan Paul Joubert

20728212

B-Pharm

Dissertation submitted in partial fulfilment of the requirements for
the degree M.Sc in Pharmaceutical Chemistry at the Potchefstroom
Campus of the North-West University

Supervisor: Prof. D.D. N'Da

Assistant-supervisor: Mr. F.J. Smit

November 2013

ACKNOWLEDGEMENTS

I would like to thank the following people and institutions for their support and contributions;

Prof. D.D. N'Da, my supervisor, for his guidance, support and enthusiasm throughout this study. David, you taught me that through hard work, commitment and faith anything is possible.

F.J. Smit, my assistant-supervisor. Without you, this study would not have been possible. Thank you for never being too busy to help.

A. Joubert, for the skilled NMR.

Dr. J. Jordaan, for the skilled NMR and MS spectra.

My parents for the continues emotional and financial support.

My **colleagues** and **friends**, Marnitz Verwy, Lizanne van Heerden, Theunis Cloete, Bennie Repsold and Rozanne Harmse

National Research Foundation (NRF), for financial support.

North-West University, for financial support.

My wife, Esti, for her love, support and encouragement through the good and bad times.

ABSTRACT

Malaria endemic areas not only pose a public health threat, but affects 3.3 billion people worldwide. In 2011, estimated malaria related deaths amounted to 660 000 out of 219 million reported cases, with 81% of these and 91% of malaria related mortality occurred in the African region. Those most affected were pregnant women, children under the age of five and immunocompromised individuals. Malaria is the fifth deadliest disease worldwide and accounts for the second highest death rate in Africa, following HIV/Aids.

To combat this parasitic infection of antiquity, the ideal malaria pharmacotherapy would be a cost effective and easily obtainable monotherapy. The malaria parasite, however, has an intrinsic ability to develop drug resistance through various mechanisms. Widespread resistance towards antimalarial drugs has rendered traditionally used drugs therapeutically ineffective, hence accentuating the efficacy of the artemisinins as first line treatment option for uncomplicated *Plasmodium falciparum* (*P. falciparum*). A devastating reality of the challenging battle against malaria is the confirmed prolonged parasitic clearance times of the artemisinins, despite adequate drug exposure, which emphasises the urgent need for identifying and developing new, effective and safe therapies.

During this study, 9-aminoacridines and artemisinin-acridine hybrids were successfully synthesised through nucleophilic substitution and their chemical structures confirmed by means of nuclear magnetic resonance spectroscopy (NMR), high resolution mass spectroscopy (HRMS) and infrared spectroscopy (IR). The hybrid compounds were synthesised through microwave assisted radiation, by covalently linking the artemisinin- and amino-functionalised acridine pharmacophores by means of a liable aminoethyl ether chain.

The target compounds were screened *in vitro* for antimalarial activity against both the chloroquine sensitive (NF54) and chloroquine resistant (Dd2) strains of *P. falciparum*. Their cytotoxicities were assessed against various mammalian cells of different origins, *viz.* the Chinese hamster ovarian cells (CHO) from animal origin, and from human origin, hepatocellular- (HepG2), neuroblastoma- (SH-SY5Y) and cervical cancer (HeLa) cells.

The synthesised hybrids exhibited antimalarial activity against both *Plasmodium* strains. Compound **7**, featuring an ethylenediamine moiety in the linker, was the most active hybrid, with 50% inhibitory concentration (IC₅₀) values of 2.6 nM and 35.3 nM against the NF54 and Dd2 strains, respectively. It had gametocytocidal activity against the NF54 strain, comparable to dihydroartemisinin (DHA) and artesunate (AS) and it is significantly more potent than

chloroquine (CQ), whilst possessing a resistance index value of 14, indicative of a significant loss of activity against the CQ resistant strain.

Contrary, the promising hybrid **10**, containing a 2-methylpiperazine linker, had gametocytocidal activity, comparable to CQ and was found to be six-fold more potent than CQ against the Dd2 strain, with a resistance index (RI) value of 2, whilst it further showed highly selective action towards the parasitic cells. Compound **10** was also found to possess anticancer activity against the HeLa cell line, comparable to DHA and AS, but fivefold higher than that of CQ, with the same levels of hepatotoxicity and neurotoxicity.

The artemisinin-acridine hybrids displayed superior antimalarial activity, compared to the derived 9-aminoacridines against both the *Plasmodium* strains. They, however, did not have the ability to overcome resistance, reduce the toxicity of acridine, nor induce synergistic activity. The hybrids, indeed displayed promising anticancer activity against HeLa cells. It is anticipated that these compounds may stand as drug candidates for further investigation in the search for new anti-cervical cancer drugs, rather than as antimalarials.

Keywords: Malaria, artemisinin, acridine, hybrids, *Plasmodium falciparum*, cytotoxicity

OPSOMMING

Malaria in endemiese gebiede bly nie net 'n openbare gesondheidskommer nie, maar raak 3.3 biljoen mense wêreldwyd. In 2011 het beraamde malaria-verwante sterftes 660 000 uit 219 miljoen aangemelde gevalle beloop, waarvan 81% van hierdie gevalle en 91% van die malaria verwante sterftes, in die Afrika-streek voorgekom. Diegene wat die meeste hierdeur geraak was, was swanger vroue, kinders onder die ouderdom van vyf jaar en immuunonderdrukte individue. Malaria is tans die vyfde dodelikste siekte wêreldwyd en is naas MIV/Vigs vir die tweede hoogste sterftesyfer in Afrika verantwoordelik.

Om hierdie parasitiese infeksie van ouds te bekamp, sou die ideale malaria-farmakoterapie 'n koste-effektiewe en maklik verkrygbare monoterapie moes wees. Die malaria-parasiet het egter die intrinsieke vermoë om weerstand teen medikasie deur verskeie meganismes te ontwikkel. Wydverspreide weerstand teen malaria-geneesmiddels het tradisioneel-voorgeskrewe medikasie terapeuties oneffektief gelaat, wat die effektiwiteit van artemisinien as eerste linie behandeling vir ongekompliseerde *Plasmodium falciparum* (*P. falciparum*) beklemtoon. Die ontstellende werklikheid van die uitdagende stryd teen malaria is die bevestigde verhoging van die parasiet se opruimingstye, ten spyte van genoegsame blootstelling aan artemisinin, wat dus die dringende noodsaaklikheid om nuwe, effektiewe en veilige behandelings te identifiseer, beklemtoon.

Tydens hierdie studie is 9-aminoakridiene en artemisinien-akridienhibriede suksesvol deur middel van nukleofiliese vervanging gesintetiseer en is hul onderskeie chemiese strukture deur middel van kernmagnetiese resonansspektroskopie (KMR), hoë resolusie massa-spektroskopie (HRMS) en infrarooi-spektroskopie (IR) bevestig. Die hibriedverbindings is deur middel van mikrogolfbestraling gesintetiseer, deur die artimisinin- en die 9-aminoakridiene-gefunksionaliseerde kovalent met behulp van 'n aminoetiel-eter-ketting te koppel.

Die teikenverbindings is *in vitro* vir malaria-aktiwiteit teen beide die chlorokiensensitiewe (NF54) en chlorokienweerstandbiedende (Dd2) stamme van *P. Falciparum* getoets. Hul sitotoksisiteit teen verskeie soogdierselle is ondersoek, naamlik Sjinese hamster ovaria-selle van dierlike oorsprong, en van menslike oorsprong, heptosellulêre selle (HepG2), neuroblastomaselle (SH-SY5Y) en servikale kankerselle (HeLa). Die gesintetiseerde hibriedverbindings het teen-malaria aktiwiteit teen beide *Plasmodium*-stamme getoon.

Verbinding **7**, wat 'n etileendiamienstruktuur in die skakel bevat, was die mees aktiefste hibried met 50% inhiberende konsentrasie (IC₅₀) waardes van 2.6 nM en 35.3 nM teen die NF54 en

Dd2 stamme, onderskeidelik. Die verbinding het ook gametositositale aktiwiteit teen NF45 getoon, vergelykbaar met dihidroartemisinien (DHA) en artesunaat (AS) en was dit aansienlik sterker as chlorokien (CQ), terwyl dit 'n weerstandsindeks-waarde van 14 getoon het, wat aanduidend van 'n beduidende verlies in aktiwiteit teen die CQ weerstandige stam was.

Hierteenoor het die belowende hibriedverbinding **10**, met 'n 2-metielpiperasien-skakel, gametositositale aktiwiteit, vergelykbaar met CQ getoon. Die verbinding is ook 6-maal sterker as CQ teen die Dd2 stam bevind, met 'n weerstandsindeks-waarde van 2, terwyl dit voorts hoogs selektiewe aktiwiteit teenoor die parasitiese selle getoon het. Daar was ook bevind dat verbinding **10** teen-kanker aktiwiteit teen die HeLa sellyn getoon het, vergelykbaar met DHA en AS, maar vyfkeer hoër as dié van CQ, met dieselfde vlakke van hepatotoksisiteit en neurotoksisiteit.

Die artemisinien-akridien hibriedverbindings het beter teen-malaria aktiwiteit as die 9-aminoakridiene teenoor beide die *Plasmodium*-stamme vertoon. Hulle het egter nie die vermoë besit om weerstand te oorkom nie, of om die toksisiteit van die akridien te verminder nie, of om sinergistiese aktiwiteit te weeg te bring nie. Die hibriedverbindings het egter belowende teen-kanker aktiwiteit teen HeLa selle vertoon. Daar word verwag dat hierdie verbindings dus as kandidaat-geneesmiddels mag staan vir verdere navorsing in die soeke na teen-servikale kankermiddels, eerder as teen-malaria-middels.

Kernwoorde: Malaria, artemisinien, akridien, hibriede, *Plasmodium falciparum*, sitotoksisiteit

PREFACE

This thesis is submitted in an article format in accordance with the General Academic Rules (A.13.7.3) of the North-West University.

The article was submitted to the European Journal of Pharmaceutical Sciences. This article is prepared according to the author's guidelines, available in the author information pack on the Journal's homepage:

<http://www.elsevier.com/journals/european-journal-of-pharmaceutical-sciences/0928-0987/guide-for-authors>

The article is submitted to Elsevier, which grants the author the right to include the article in a thesis. Permission from Elsevier, as per website:

<http://www.elsevier.com/journal-authors/author-rights-and-responsibilities>

TABLE OF CONTENTS

ACKNOWLEDGEMENTS	i
ABSTRACT	ii
OPSOMMING	iv
PREFACE	vi
TABLE OF CONTENTS	vii
LIST OF TABLES TABLE OF FIGURES	xi
LIST OF SCHEMES	xiii
LIST OF ABBREVIATIONS	xiv

CHAPTER 1: INTRODUCTION AND PROBLEM STATEMENT

1.1	Introduction	1
1.2	Aim and objectives of the study.....	4

CHAPTER 2: LITERATURE REVIEW

2.1	Introduction	5
2.2	Geographical prevalence	5
2.3	South Africa	7
2.4	Clinical manifestations	9
2.5	Diagnosis	10
2.5.1	Clinical diagnosis.....	10
2.5.2	Microscopy	10
2.5.3	Antigen based rapid diagnostic tests (RDT's)	11
2.5.4	Serology	11
2.6	Life cycle.....	11
2.6.1	Plasmodium falciparum life cycle in the human host.....	12
2.6.2	Plasmodium falciparum life cycle in the mosquito.....	14
2.7	Malaria elimination, control and treatment.....	14
2.8	Chemotherapy	15
2.8.1	Antifolates and sulphas	15
2.8.1.1	Class I.....	16
2.8.1.2	Class II.....	17
2.8.1.3	Resistance to antifolate drugs	19
2.8.2	4-Aminoquinolines.....	19

2.8.2.1	Resistance to 4-aminoquinolines.....	20
2.8.3	Aryl-amino alcohols	20
2.8.3.1	Resistance to aryl-amino alcohols	22
2.8.4	8-Aminoquinolines.....	22
2.8.4.1	Resistance to primaquine.....	23
2.8.5	Antibiotics.....	23
2.8.6	Synthetic acridines	24
2.8.6.1	Acridine alkaloids	26
2.8.6.2	Mechanism of action	27
2.8.6.3	Toxicity.....	27
2.8.7	Artemisinins.....	27
2.8.7.1	Metabolism.....	28
2.8.7.2	Cytotoxicity.....	29
2.8.7.3	Clinical tolerance.....	29
2.8.7.4	Artemisinin based combination therapies (ACT's)	29
2.8.7.5	Modes of action and potential cellular targets.....	30
2.8.7.5.1	<i>Activation of artemisinin (open ring model) and production of free radicals</i>	30
2.8.7.5.2	<i>Targeting haem polymerisation</i>	31
2.8.7.5.3	<i>Targeting PfATP6 and mitochondrial targets</i>	31
2.9	Hybrid theory	31
2.9.1	Acridine based hybrids	33
2.9.2	Artemisinin based hybrids	33
2.10	Antimalarials in the pipeline.....	34

CHAPTER 3: ARTICLE FOR SUBMISSION

Abstract.....	39
1. Introduction	39
2. Materials and Methods.....	40
2.1. Materials	40
2.2. General procedures	40
2.3. Synthesis	41
2.3.1. 2-Bromo-(10 β -dihydroartemisinoxy)ethane, 1	41
2.3.2. 9-Aminoacridines, 2 – 6	41
2.3.2.1. N-(2-aminoethyl)-6-chloro-2-methoxyacridin-9-amine, 2	41
2.3.2.2. {3-[(6-chloro-2-methoxyacridin-9-yl)amino]propyl}(methyl)amine, 3	41
2.3.2.3. 6-chloro-2-methoxy-9-(piperazin-1-yl)acridine, 4	41
2.3.2.4. 6-chloro-2-methoxy-9-(3-methylpiperazin-1-yl)acridine, 5	41

2.3.2.5.	6-chloro-2-methoxy-N-[2-(piperazin-1-yl)ethyl]acridin-9-amine, 6	42
2.3.3.	Artemisinin-acridine hybrids, 6 – 11	42
2.3.3.1.	{N-(2-aminoethyl)-6-chloro-2-methoxyacridin-9-amine}-2-(10 β - dihydroartemisinoxy)ethane, 7	42
2.3.3.2.	{3-[(6-chloro-2-methoxyacridin-9-yl)amino]propyl}(methyl)amine-2-(10 β - dihydroartemisinoxy)ethane, 8	43
2.3.3.3.	6-chloro-2-methoxy-9-(piperazin-1-yl)acridine-2-(10 β -dihydroartemisino- xy)ethane, 9	43
2.3.3.4.	6-chloro-2-methoxy-9-(2-methylpiperazin-1-yl)acridine-2-(10 β -dihydroarte- misinoxy)ethane, 10	43
2.3.3.5.	6-chloro-2-methoxy-N-[2-(piperazin-1-yl)ethyl]acridin-9-amine-2-(10 β - dihydroartemisinoxy)ethane, 11	43
2.4.	Physicochemical properties.....	44
2.5.	<i>In vitro</i> biological evaluation	44
2.5.1.	Antimalarial activity.....	44
2.5.2.	Cytotoxicity and anticancer activity	44
2.5.3.	Apoptosis	45
3.	Results.....	45
3.1.	Chemistry.....	45
3.2.	Physicochemical properties.....	46
3.3.	<i>In vitro</i> antimalarial activity and cytotoxicity	46
4.	Discussion	46
4.1.	Chemistry.....	46
4.2.	Physicochemical/pharmacokinetic properties	47
4.3.	<i>In vitro</i> biological evaluation	48
5.	Conclusion	49
	References.....	49

CHAPTER 4: SUMMARY AND CONCLUSION

Summary and conclusion	51
------------------------------	----

REFERENCES

References.....	55
-----------------	----

APPENDIX A: SPECTRA

Appendix A: Spectra.....70

APPENDIX B: GUIDE FOR AUTHORS

Appendix B: Guide for authors.....96

LIST OF TABLES AND FIGURES

CHAPTER 1: INTRODUCTION AND PROBLEM STATEMENT

Figure 1.1: Structures of artemisinin and its derivatives	1
Figure 1.2: Structures of acridine derivatives	3

CHAPTER 2: LITERATURE REVIEW

Figure 2.1: Areas of malaria transmission.....	6
Figure 2.2: Malaria risk in South Africa	8
Figure 2.3: Malaria notifications for South Africa in 2010. Provinces: Limpopo (L); Mpumalanga (MP); KwaZulu-Natal (KZN); North-West (NW); Gauteng (GP); Northern Cape (NC); Eastern Cape (EC); Western Cape (WC); Free State (FS).....	9
Figure 2.4: The life cycle of the malaria parasite.....	12
Figure 2.5: Structure of folic acid (1).....	16
Figure 2.6: Biosynthetic pathway of tetrahydrofolic acid.....	16
Figure 2.7: Structures of dapsone (2) and sulphalene (3)	17
Figure 2.8: Structures of proguanil (4), proguanil prodrug, chlorproguanil (5) and proguanil's active metabolite, cycloguanil (6).....	18
Figure 2.9: Structures of pyrimethamine (7).....	18
Figure 2.10: Structures of the 4-aminoquinoline compounds, chloroquine (8) and amodiaquine (9).....	20
Figure 2.11: Structures of the diastereomers, quinine (10) and quinidine (11)	21
Figure 2.12: Structures of mefloquine (12) as a racemate and halofantrine (13).....	22
Figure 2.13: Structures of primaquine (14).....	23
Figure 2.14: Structures of doxycycline (15).....	24
Figure 2.15: Structures of quinacrine (16) and pyronaridine (17)	25
Figure 2.16: Structures of 2-methoxy-6-chloro-9 aminoacridine (18) 3,6-diamino-1'-amino-9-anilinoacridine (19) and 1'-dimethylamino-3,6-diamino-9-anilinoacridine (20)	25
Figure 2.17: Structures of WR 243251 (21) and 3-(5,6,6,6-Tetrafluoro-5-trifluoromethyl-hexyloxy)-6-chloroacridinone (22).....	26
Figure 2.18: Structures of 2-nitroacronycine (23) and atalaphillidine (24)	27
Figure 2.19: Structures of artemisinin derivatives, artemisinin (25), dihydroartemisinin (26), artemether (27) and artesunate (28).....	28

Figure 2.20: Illustration of hybrid drug theory.....	32
Figure 2.21: Structures of azithromycin (29), quinocide (30) and tafenoquine (31)	35
Figure 2.22: Structures of arteolane (32) artemisone (33) daphnetin (34), 5,7-methoxy-8-(3-methyl-1-buten-3-ol)-coumarin (35) and pachyrrhizine (36).....	37

CHAPTER 3: ARTICLE FOR SUBMISSION

Figure 1: Structures of artemisinins	40
Figure 2: Structure of mepacrine	40
Figure 3: The 2-bromo-(10 β -dihydroartemisinoxy)ethane analogue of DHA	41
Table 1: TGA and DSC data of compounds 7 - 11 and DHA	44
Table 2: Predicted physicochemical parameters of compounds 2 - 11 (Accelrys Discovery Studio 3.1 served to calculate the predicted values).....	44
Table 3: <i>In vitro</i> biological activity of compounds	45

LIST OF SCHEMES

Scheme 1: Multi-step synthesis of artemisinin-acridine hybrids 7 – 11	42
---	----

LIST OF ABBREVIATIONS

ACT	Artemisinin-based combination therapy
APCI	Atmospheric pressure chemical ionization
AS	Artesunate
BBB	Blood brain barrier
CDC	Centre for disease control
CHO	Chinese hamster ovarian
CQ	Chloroquine
CQR	Chloroquine resistant
CQS	Chloroquine sensitive
DCM	Dichloromethane
DHA	Dihydroartemisinin
DHF	Dihydrofolate
DHFR	Dihydrofolate reductase
DHPS	Dihydropteroate synthase
DMF	N,N-dimethylformamide
DMSO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid
DSC	Differential scanning calorimetry
ESI	Electrospray ionization
EtOAc	Ethyl acetate
HepG2	Human hepatocellular cells
HIV	Human immunodeficiency virus
HRMS	High resolution mass spectrometry
IR	Infrared
IRS	Indoor residual spraying
MeOH	Methanol
NADH	Nicotinamide adenine dinucleotide
NADPH	Adenine dinucleotide phosphate
NH ₄ OH	Ammonium hydroxide
NMR	Nuclear magnetic resonance
PABA	<i>p</i> -Aminobenzoic acid
PfATP6	<i>Plasmodium falciparum</i> chloroquine resistance transporter
PfHRP	<i>Plasmodium falciparum</i> histidine rich protein
PfMDR1	<i>Plasmodium falciparum</i> multidrug resistance 1
RDT's	Rapid diagnostic tests

RI	Resistance index
ROS	Reactive oxygen species
SD	Standard deviation
SERCA	Sarcoplasmic/endoplasmic reticulum Ca ²⁺ -ATPase
SH-SY5Y	Human neuroblastoma cells
SR	Sarcoplasmic reticulum
TGA	Thermal gravimetric analysis
THF	Tetrahydrofuran
WHO	World Health Organisation
WRAIR	Walter Reed Army Institute of Research